The World Health Organization (WHO) has marked a significant milestone in the fight against malaria with the prequalification of the R21/Matrix-M malaria vaccine, as announced on December 21, 2023. This development represents a major leap forward in the global health community’s efforts to combat one of the most persistent and deadly diseases, particularly in the African Region where it disproportionately affects children.
The R21/Matrix-M vaccine, developed by Oxford University and manufactured by the Serum Institute of India, is the second malaria vaccine to receive WHO prequalification, following the RTS,S/AS01 vaccine, which was prequalified in July 2022.
Malaria, a mosquito-borne disease, has been a longstanding public health challenge, particularly in sub-Saharan Africa. In 2022, there were an estimated 249 million cases of malaria worldwide, resulting in 608,000 deaths, with a significant number of these being children under the age of five. The prequalification of the R21/Matrix-M vaccine is a crucial step in addressing this challenge, as it opens the door for broader access to effective preventive measures against malaria.
Prequalification by WHO is a signal to countries and funding agencies, such as UNICEF and Gavi, the Vaccine Alliance, that the vaccine meets global standards for safety and efficacy, and is suitable for procurement and widespread use.
The addition of the R21/Matrix-M vaccine to the arsenal against malaria is expected to have a substantial impact on public health. Both the R21/Matrix-M and RTS,S/AS01 vaccines have demonstrated safety and effectiveness in clinical trials, particularly in preventing malaria among children. When used in conjunction with other malaria control interventions, such as mosquito nets and antimalarial drugs, these vaccines are expected to significantly reduce the incidence of malaria and the number of deaths caused by the disease.
The prequalification of this second malaria vaccine is particularly significant given the high demand for malaria vaccines in African countries and the previously limited supply. With two WHO-recommended and prequalified vaccines now available, it is anticipated that there will be an increase in the supply of vaccines to meet this demand. This will ensure that sufficient doses are available to protect all children living in areas where malaria is a significant public health risk.
Dr. Kate O’Brien, Director of WHO’s Department of Immunization, Vaccines and Biologicals, highlighted the importance of this milestone, stating that it represents a huge stride in global health and underscores WHO’s commitment to eradicating malaria. She emphasized that malaria remains a formidable foe causing child suffering and death, and the prequalification of the R21/Matrix-M vaccine is a step toward ensuring a healthier, more resilient future for those most vulnerable to the disease.
The WHO’s prequalification process involves a comprehensive evaluation of vaccines to ensure they meet international standards for safety, efficacy, and manufacturing quality. This process also includes ongoing measures to ensure the continued safety and efficacy of prequalified vaccines, such as regular re-evaluation, site inspections, and targeted testing. This rigorous process supports the specific needs of national immunization programs and ensures that vaccines are suitable for use in the targeted health systems.
In conclusion, the WHO’s prequalification of the R21/Matrix-M malaria vaccine is a landmark achievement in the global fight against malaria. It represents a significant step forward in ensuring greater access to safe, effective, and quality health products, particularly for children in malaria-endemic areas. This development is a testament to the relentless efforts of the global health community to combat malaria and protect the lives of millions of children at risk of this deadly disease.
News Reference
WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease. (n.d.). Retrieved from https://www.who.int/news/item/21-12-2023-who-prequalifies-a-second-malaria-vaccine-a-significant-milestone-in-prevention-of-the-disease
